All Data
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
First Phase 3 trial in eosinophilic esophagitis (EoE) to show a biologic medicine significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE).
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
Dupixent’s unique mechanism of action simultaneously inhibits IL-4 and IL-13. Recent evidence further supports additional clinical uses in diseases driven by type 2 inflammation including Eosinophilic Esophagitis and a subset of Chronic Obstructive Pulmonary Disease .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Gastroenterology Product Name: APT-1011
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
Ellodi Pharmaceuticals is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Risankizumab
Therapeutic Area: Gastroenterology Product Name: Skyrizi
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Pennsylvania University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
A significantly greater proportion of patients with Crohn's disease treated with either dose of risankizumab achieved both primary endpoints, demonstrating statistically significant results for clinical remission and endoscopic response at week 12 compared to placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Upadacitinib
Therapeutic Area: Gastroenterology Product Name: Rinvoq
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Significantly more upadacitinib-treated (45 mg) patients achieved clinical remission (primary endpoint per Adapted Mayo Score) at week 8 compared to placebo in adults with moderate to severe ulcerative colitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Carotegrast Methyl
Therapeutic Area: Gastroenterology Product Name: AJM300
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: EA Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
Primary endpoint was achieved in Phase III clinical study (AJM300/CT3) of AJM300 (nonproprietary name: carotegrast methyl), which EA Pharma and Kissei Pharmaceutical have developed for treatment of ulcerative colitis.